Product Description
Didanosine is used along with other medications to treat human immunodeficiency virus (HIV) infection. Didanosine is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV in the blood. Although didanosine does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV virus to other people (Sourced from: https://medlineplus.gov/druginfo/meds/a691006.html)
Mechanisms of Action: RTI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Dominican Republic | France | Germany | Hungary | India | Ireland | Italy | Malta | Morocco | New Zealand | Pakistan | Peru | Portugal | Russia | Slovenia | South Africa | Spain | Sweden | Taiwan | Thailand | United Kingdom | Venezuela | Vietnam
Approved Indications: HIV Infections
Known Adverse Events: Abdominal Pain | Headache | Pain Unspecified | Diarrhea
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|